Paul Imbach – författare

This practical manual, written by well-known experts, reviews current indications for the use of IgG concentrates and some other modern immunomodulators and provides fundamental information on present-day immunomodulation in patients (and mice).

This is the third edition of a well-received compendium of information and guidance on the diagnosis and management of the various oncological diseases that are encountered in children and adolescents.

This is the third edition of a well-received compendium of information and guidance on the diagnosis and management of the various oncological diseases that are encountered in children and adolescents. In the new edition a chapter on Rare Tumors was added. For each disease entity, fundamental facts are provided that will be relevant for a range of professionals – hospital physicians, specialist nurses, psycho-oncologists, physiotherapists, family doctors and pediatricians. Compared with the first edition all chapters have been updated. Throughout, rapid orientation is ensured by the clear, consistent layout and the concise, lucid style. Pediatric Oncology: A Comprehensive Guide is an excellent, easy-to-use reference that belongs on the shelf of every practitioner who encounters or treats malignancies in the pediatric age group. Pediatric Oncology is teamwork! Fundamental facts for all those involved in diagnosis and management – even social worker, pedagogic teachers, religious care persons.

This practical manual, written by well-known experts, reviews current indications for the use of IgG concentrates and some other modern immunomodulators and provides fundamental information on present-day immunomodulation in patients (and mice). The book opens by tracing the transition from IgG substitution to IgG immunomodulation and providing expert updates on immunomodulatory indications in autoimmune and inflammatory disorders, including hematologic, neurologic, dermatologic, and other diseases. Basic aspects of IgG concentrates, including methods of production, safety, currently available products, and mechanisms of action, are then discussed. An entire chapter is devoted to the different aspects of immunomodulatory IgG treatment in the bleeding disorder immune thrombocytopenia (ITP). Finally, the transition from polyclonal to monoclonal antibody (mAb) treatment is addressed in detail, covering mAb development, methods, mechanisms of action, adverse effects, and more. Particular attention is paid to the example of anti-CD20 (B-cell) antibody.